Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.

B isphosphonates are increasingly being incorporated in the management of patients with breast cancer.[1] With wider adoption of bisphosphonates, the incidence of some rare complications like hypocalcaemia might go up, particularly in vitamin D deficient populations. Here we would like to share our experience of managing a patient, who developed symptomatic hypocalcaemia after intravenous (IV) infusion of zoledronic acid, to highlight the need of anticipating this preventable, and potentially fatal complication.